These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378 [TBL] [Abstract][Full Text] [Related]
8. BCL11A expression in acute phase chronic myeloid leukemia. Yin J; Zhang F; Tao H; Ma X; Su G; Xie X; Xu Z; Zheng Y; Liu H; He C; Mao ZJ; Wang Z; Chang W; Gale RP; Wu D; Yin B Leuk Res; 2016 Aug; 47():88-92. PubMed ID: 27285855 [TBL] [Abstract][Full Text] [Related]
9. Bcl11a is essential for lymphoid development and negatively regulates p53. Yu Y; Wang J; Khaled W; Burke S; Li P; Chen X; Yang W; Jenkins NA; Copeland NG; Zhang S; Liu P J Exp Med; 2012 Dec; 209(13):2467-83. PubMed ID: 23230003 [TBL] [Abstract][Full Text] [Related]
10. Somatic SETBP1 mutations in myeloid neoplasms. Makishima H Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248 [TBL] [Abstract][Full Text] [Related]
11. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. Cutts BA; Sjogren AK; Andersson KM; Wahlstrom AM; Karlsson C; Swolin B; Bergo MO Blood; 2009 Oct; 114(17):3629-32. PubMed ID: 19710506 [TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Lu D; Nounou R; Beran M; Estey E; Manshouri T; Kantarjian H; Keating MJ; Albitar M Cancer; 2003 Jan; 97(2):441-9. PubMed ID: 12518368 [TBL] [Abstract][Full Text] [Related]
13. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Kalra R; Paderanga DC; Olson K; Shannon KM Blood; 1994 Nov; 84(10):3435-9. PubMed ID: 7949098 [TBL] [Abstract][Full Text] [Related]
14. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1. Steinemann D; Arning L; Praulich I; Stuhrmann M; Hasle H; Stary J; Schlegelberger B; Niemeyer CM; Flotho C Haematologica; 2010 Feb; 95(2):320-3. PubMed ID: 20015894 [TBL] [Abstract][Full Text] [Related]
15. Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice. Pelletier SD; Hong DS; Hu Y; Liu Y; Li S Blood; 2004 Oct; 104(7):2163-71. PubMed ID: 15213099 [TBL] [Abstract][Full Text] [Related]
16. Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Yang G; Khalaf W; van de Locht L; Jansen JH; Gao M; Thompson MA; van der Reijden BA; Gutmann DH; Delwel R; Clapp DW; Hiebert SW Mol Cell Biol; 2005 Jul; 25(14):5869-79. PubMed ID: 15988004 [TBL] [Abstract][Full Text] [Related]
17. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity. Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690 [TBL] [Abstract][Full Text] [Related]